A Phase 3 interventional study of Alirocumab and Ezetimibe in Hypercholesterolemia, sponsored by Sanofi. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-06.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 23rd largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 16th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 24th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 18th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
Primary Objective of the study:
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab in comparison with ezetimibe after 24 weeks of treatment in participants with hypercholesterolemia.
Secondary Objectives:
The maximum study duration was 34 weeks per participant, including a 24-week randomized treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
Drug: Ezetimibe · Drug: Placebo (for Alirocumab)
SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
Drug: Alirocumab · Drug: Placebo (for Ezetimibe)
1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
Also known as: SAR236553, REGN727
One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
One capsule orally once daily at approximately the same time of the day with or without food..
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
Time frame: Up to Week 24
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 from multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
The study was conducted at 8 centers in 4 countries. A total of 204 participants were screened between July 2012 and November 2012, 101 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Started | 51 | 52 |
| Treated | 51 | 52 |
| Completed | 44 | 44 |
| Not completed | 7 | 8 |
| Withdrew: Poor compliance to protocol | 1 | 0 |
| Withdrew: Consent withdrawn by participant | 0 | 1 |
| Withdrew: Participant moved | 0 | 1 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Site scheduling error | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis | -15.6 ± 3.1 | -47.2 ± 3.0 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | -19.6 ± 2.6 | -48.1 ± 2.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis | -11.0 ± 2.4 | -36.7 ± 2.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | -15.1 ± 2.9 | -40.6 ± 2.8 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | -10.9 ± 2.2 | -29.6 ± 2.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | -11.7 ± 2.1 | -37.3 ± 2.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | -16.7 ± 2.4 | -42.5 ± 2.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | -12.0 ± 1.7 | -30.3 ± 1.7 |
Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
| percentage of participants | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis | 32.2 | 88.1 |
Adjusted percentages at Week 24 from multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percentage of participants | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 2.4 | 59.4 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | -12.3 ± 3.8 | -16.7 ± 3.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 1.6 ± 1.9 | 6.0 ± 1.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | 1.6 ± 2.0 | 9.0 ± 2.0 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | -14.2 ± 3.7 | -17.2 ± 3.7 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | -10.8 ± 4.3 | -11.9 ± 4.2 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | -2.3 ± 3.5 | -12.2 ± 3.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis | -0.6 ± 1.6 | 4.7 ± 1.6 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | -2.2 ± 1.4 | 2.3 ± 1.4 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32 post-treatment follow-up visit) regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe 10 mg | — | 1/51 (2%) | 27/51 (52.9%) |
| Alirocumab 75/Up150 mg Q2W | — | 1/52 (1.9%) | 25/52 (48.1%) |
| Event | Ezetimibe 10 mg | Alirocumab 75/Up150 mg Q2W |
|---|---|---|
| Bone erosionMusculoskeletal and connective tissue disorders | 1/51 | 0/52 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/51 | 1/52 |
| Event | Ezetimibe 10 mg | Alirocumab 75/Up150 mg Q2W |
|---|---|---|
| NasopharyngitisInfections and infestations | 8/51 | 12/52 |
| InfluenzaInfections and infestations | 3/51 | 6/52 |
| DiarrhoeaGastrointestinal disorders | 2/51 | 6/52 |
| Upper respiratory tract infectionInfections and infestations | 5/51 | 2/52 |
| Urinary tract infectionInfections and infestations | 3/51 | 0/52 |
| DizzinessNervous system disorders | 3/51 | 1/52 |
| NauseaGastrointestinal disorders | 3/51 | 3/52 |
| Back painMusculoskeletal and connective tissue disorders | 3/51 | 1/52 |
| HeadacheNervous system disorders | 2/51 | 3/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/51 | 3/52 |
| Age, Continuous(years) | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 59.6 ± 5.3 | 60.8 ± 4.6 | 60.2 ± 5.0 |
| Sex: Female, Male(Participants) | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Female | 24 | 24 | 48 |
| Male | 27 | 28 | 55 |
| Calculated LDL-C in mmol/L(mmol/L) | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 3.58 ± 0.6 | 3.65 ± 0.7 | 3.62 ± 0.7 |
| Calculated LDL-C in mg/dL(mg/dL) | Ezetimibe 10 mg | Alirocumab 75/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 138.3 ± 24.5 | 141.1 ± 27.1 | 139.7 ± 25.8 |
The record gives a start of Jul 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 2 years 4 months after primary completion. A results delay was requested in Jul 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab